FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced ...
Geron (GERN) announced results from an oral presentation at the 66th American Society of Hematology, or ASH, annual meeting, reporting Phase 1 findings from the two-part IMproveMF study. The safety ...
- Preclinical data showed synergistic and additive effects of combination imetelstat and ruxolitinib - Study intended to explore potential for disease modification with imetelstat in earlier, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results